China SXT Pharmaceuticals (NASDAQ:SXTC) Shares Scheduled to Reverse Split on Monday, August 10th

Shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) are set to reverse split on Monday, August 10th. The 1-80 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 9th.

China SXT Pharmaceuticals Trading Down 19.6%

Shares of NASDAQ:SXTC traded down $0.01 during trading on Thursday, reaching $0.05. 46,705,100 shares of the company traded hands, compared to its average volume of 15,593,663. China SXT Pharmaceuticals has a 52 week low of $0.05 and a 52 week high of $1,046.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.76 and a current ratio of 7.94. The company’s 50 day moving average is $1.76 and its two-hundred day moving average is $2.66.

China SXT Pharmaceuticals (NASDAQ:SXTC) last issued its quarterly earnings results on Wednesday, July 1st. The company reported ($0.07) EPS for the quarter. The company had revenue of $0.26 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Investors Weigh In On China SXT Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC increased its position in China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after acquiring an additional 15,013 shares during the period. XTX Topco Ltd acquired a new stake in China SXT Pharmaceuticals in the fourth quarter valued at $36,000. Finally, Citadel Advisors LLC bought a new position in China SXT Pharmaceuticals during the 3rd quarter worth $78,000. 5.02% of the stock is currently owned by institutional investors and hedge funds.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.